EP0897283B1 - Analysis for the presence of degenerative brain disease - Google Patents

Analysis for the presence of degenerative brain disease Download PDF

Info

Publication number
EP0897283B1
EP0897283B1 EP97916578A EP97916578A EP0897283B1 EP 0897283 B1 EP0897283 B1 EP 0897283B1 EP 97916578 A EP97916578 A EP 97916578A EP 97916578 A EP97916578 A EP 97916578A EP 0897283 B1 EP0897283 B1 EP 0897283B1
Authority
EP
European Patent Office
Prior art keywords
animals
rsa
measure
respiratory
slaughter
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP97916578A
Other languages
German (de)
French (fr)
Other versions
EP0897283A1 (en
Inventor
Christopher Pomfrett
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Victoria University of Manchester
Original Assignee
Victoria University of Manchester
University of Manchester
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB9607970A external-priority patent/GB9607970D0/en
Priority claimed from GB9623759A external-priority patent/GB9623759D0/en
Priority claimed from GB9704300A external-priority patent/GB9704300D0/en
Application filed by Victoria University of Manchester, University of Manchester filed Critical Victoria University of Manchester
Priority to DK97916578T priority Critical patent/DK0897283T3/en
Publication of EP0897283A1 publication Critical patent/EP0897283A1/en
Application granted granted Critical
Publication of EP0897283B1 publication Critical patent/EP0897283B1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/02Detecting, measuring or recording pulse, heart rate, blood pressure or blood flow; Combined pulse/heart-rate/blood pressure determination; Evaluating a cardiovascular condition not otherwise provided for, e.g. using combinations of techniques provided for in this group with electrocardiography or electroauscultation; Heart catheters for measuring blood pressure
    • A61B5/024Detecting, measuring or recording pulse rate or heart rate
    • A61B5/0245Detecting, measuring or recording pulse rate or heart rate by using sensing means generating electric signals, i.e. ECG signals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/40Detecting, measuring or recording for evaluating the nervous system
    • A61B5/4076Diagnosing or monitoring particular conditions of the nervous system
    • A61B5/4088Diagnosing of monitoring cognitive diseases, e.g. Alzheimer, prion diseases or dementia

Definitions

  • BSE bovine spongiform encephalopathy
  • the invention also provides an animal carcass selection apparatus, comprising monitoring means for deriving a measure of the respiratory sinus arrhythmia of animals prior to slaughter, and means for comparing this measure with a reference value or range and hence producing an output indicating whether or not individual animals have normal RSA, the output being used to enable the selection of carcasses of only those animals for which the output indicates normal RSA.
  • the paper by Genovely and Pfeifer referred to above sets out various analysis methods including the "mean circular resultant" method which relies upon the degree of clustering of R-waves relative to the respiratory cycle. This is a suitable method to be used in measuring RSA in methods in accordance with the present invention.
  • RSA may also be measured in other ways, for example by fitting only an ECG monitor to the animal, and analysing the spectral components of an ECG tachygram derived from the monitor, i.e. the beat to beat variations in heart rate. RSA appears as a high frequency peak coincident with the respiratory frequency.
  • the lungs 1 expand and contract as a result of normal respiration. Stretch receptors in the wall of the lungs generate signals which are transmitted over nerves represented by line 2 to the brain stem or medulla 3. Signals from the medulla are transmitted on nerves represented by the line 4 to the heart 5. Damage to the medulla will also of course disrupt the transmission of signals from the cerebral cortex 6 but damage to the cerebral cortex will not directly affect the lungs/brain/heart control loop.
  • Figure 3 represents outputs which can be expected from a healthy mammal.
  • the regular line 12 represents the reference level.
  • the irregular line 13 represents the measured RSA. It will be noted that the two signals are of the same order of magnitude and that the signal 13 is sometimes greater than and sometime less than the reference level 12.
  • Figure 4 represents outputs which can be expected from a mammal in which the lung/brain/heart control loop has been disrupted for example as a result of diabetes, anaesthesia or the formation of lesions in the brain stem.
  • the line 12 remains much as it would be in a healthy subject. This indicates that good quality data is being assessed.
  • the line 13 indicates a greatly suppressed RSA level which is substantially constant over time. The two cases illustrated in Figures 3 and 4 are clearly distinguishable.
  • ECG electrocardiogram

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Physiology (AREA)
  • Cardiology (AREA)
  • Pathology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Surgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Developmental Disabilities (AREA)
  • Hospice & Palliative Care (AREA)
  • Signal Processing (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Neurosurgery (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Apparatus For Radiation Diagnosis (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A method for detecting for the presence of a degenerative brain disease such as BSE or CJD. A measurement is made of the respiratory sinus arrhythmia of any mammal which is suspected of suffering from the degenerative brain disease. It is assumed that the mammal is suffering from such a disease if the measured RSA is outside a predetermined reference range. The reference range may be determined from data which forms the basis for the calculation of the RSA range by applying a suitable test for randomness.

Description

The present invention relates to analysis for the presence of degenerative brain disease.
Increasing public and scientific concern has been expressed about the possibility of bovine spongiform encephalopathy (hereinafter BSE) being transmitted to the human population as a result of consumption of products derived from infected cattle. It has been postulated that British cattle have become infected with BSE as the result of eating feed including products derived from sheep that have been infected with scrapie. It has also been postulated that BSE has developed as the result of the nervous systems of cattle being damaged by pesticides. Regardless of the origins of the disease, it has been suggested that cattle suffering from BSE should be slaughtered and their carcasses should not be introduced into the human food chain.
Given that BSE takes typically five or more years to become manifest as the result of the behaviour of an infected animal, and that there has heretofore been no accepted method of assessing the probability of whether or not a particular cow is suffering from BSE other than examining the brain of the slaughtered animal, it has been suggested that the only safe approach to adopt which will in addition calm public fears about the safety of eating beef products is widespread slaughter. It is almost inevitable that such a policy will result in the slaughter of many thousands of cattle which are not infected with BSE.
It is known that information regarding the status of the central nervous system of mammals can be derived from the quantification of heart rate variability. For example, the paper "Respiratory sinus arrhythmia during recovery from isoflurane-nitrous oxide anaesthesia" by Donchin, Feld, and Porges, Anesth Analg 1985; 64:811-15 states that respiratory sinus arrhythmia (hereafter RSA) may provide a physiological index of the level of anaesthesia. That same paper refers to work dating back to as early as 1935 which indicated that RSA disappeared during the induction of ether anaesthesia.
It is also known that RSA is suppressed in diabetics. Details of a method for measuring RSA to enable the identification of diabetics which method relies upon the application of circular statistics to data derived from patients is given in the paper "RR-variation: the autonomic test of choice in diabetes", by Genovely and Pfeifer, Diabetes/Metabolism Reviews, volume 4, No. 3, 255-271(1988), John Wiley & Sons Inc.
Published International Patent Application No. WO92/06632 describes a method of monitoring the depth of anaesthesia by deriving a measurement of RSA from an analysis of the position of R-waves relative to the respiratory cycle and comparing the measured RSA with a reference value obtained from the analysed .series of R-waves. This method provides a reliable indication of the depth of anaesthesia which is of use to an anaesthetist as the measure of the depth of anaesthesia can be obtained sufficiently quickly for that measurement to be used in the control of the administration of anaesthetics.
It is apparent from the above documents and references cited in those documents that RSA variation provides an indication of the state of the cardiovascular autonomic nervous system function and that the measurement of RSA may be of value in assessing depth of anaesthesia and in the identification of diabetics.
A review of recent publication has been conducted in an attempt to understand the structural changes which occur in the brains of mammals infected with BSE and similar spongiform degenerative brains diseases such as Creutzfeldt-Jakob disease (CJD). The results are summarised below.
A paper by M.Jeffery and W.G.Halliday entitled "Numbers of neurons in vacuolated and non-vacuolated neuroanatomical nuclei in bovine spongiform encephalopathy - affected brains", Journal of Comparative Pathology 110(3):287-293 reports studies of the brains of seven cows affected by BSE. These studies revealed that in infected animals there was an inconsistent degree of neuronal perikaryonal vacuolation in the dorsal vagal nucleus.
The abstract of a paper by A.Yagishita entitled "Computered tomography of Creutzfeldt-Jakob disease", in the Journal Rinsho Hoshasen, 34(11)P1317-25, 1989, noted marked atrophy of the cortex, brainstem and cerebellum.
A paper by G.A.H.Wells and J.W.Wilesmith entitled "The neuropathology and epidemiology of the bovine spongiform encephalopathy", Brain Pathology, 5(1):91-103, 1995 refers to the histopathological diagnosis of BSE, validated on a section of the medulla, and to neuronal loss in BSE which may make an important contribution to functional deficits.
RSA is a measure of the activity in the reflex loop defined between the lungs, brain and heart. The lungs feed data to the medulla of the brain stem which produces outputs transmitted via the vagal nerve to the heart to control heart rate. This reflex control loop is disrupted in diabetics as a result of damage to the vagal nerve and is disrupted by the administration of anaesthetic as a result of depression of brain stem activity. The present invention is based on a realisation that BSE and similar degenerative brain diseases are likely to disrupt the operation of the lungs/brain/heart reflex control loop and, given that RSA is an indicator of disruption to that control loop, it can also be used as an indicator of BSE.
The document Int. J. Clin. Monitoring and Computing 10 (1993), 181-185; L.G. Lacquaniti et al: "Heart Rate Variability........" includes a discussion stating that power spectrum analysis of heart rate variability is a quantitative non-invasive method for assessing neural cardiovascular control in animals and humans, and reports findings that confirmed an absence of heart rate variability in the case of severe brain damage. The findings were based on ECG monitoring of the subjects hearts during mechanical ventilation of the subjects.
Patent publication WO-A-8402641 refers on page 7 to the relationship between higher order central nervous system disorders and the vagal efferent influence on the heart, and in particular suggests that the amplitude of the heart period oscillation in the respiratory band (RSA) may provide a "window to the brain" and an early assessment screening of central nervous system dysfunction, and suggests on page 12 that the amplitude of the RSA may be employed as an index of central nervous system disfunction or influence.
It is an object of the present invention to make use of an assessment of RSA in mammals to assist in the management of animal herds subject to degenerative brain diseases such as BSE.
According to the present invention, there is provided a method for selecting mammalian animal carcasses for introduction into the human food chain, wherein before slaughter the respiratory sinus arrhythmia of the animals to be slaughtered is measured, and only those carcasses from animals for which the associated RSA is normal are selected.
The invention also provides a method for selecting mammalian animals for slaughter, wherein the respiratory sinus arrhythmia of the animals is -assessed, and animals with an abnormal measured RSA are slaughtered.
The invention also provides an animal carcass selection apparatus, comprising monitoring means for deriving a measure of the respiratory sinus arrhythmia of animals prior to slaughter, and means for comparing this measure with a reference value or range and hence producing an output indicating whether or not individual animals have normal RSA, the output being used to enable the selection of carcasses of only those animals for which the output indicates normal RSA.
The invention also provides a selection apparatus for selecting animals for slaughter, comprising monitoring means for deriving a measure of the respiratory sinus arrhythmia of the animals, and means for comparing this measure with a reference value or range and hence producing an output indicating which animals have an abnormal measured RSA to enable the slaughter of such animals.
It is believed that BSE and similar degenerative brain diseases generally characterised as being spongiform in nature result in lesions in the brain well before brain disfunction resulting from the progression of such lesions becomes apparent. Accordingly, although an assessment of the RSA of for example a cow cannot provide more than a rough guide as to whether or not that animals has BSE, it can be assumed that an animal with a normal RSA level is not suffering from the disease. Accordingly the invention provides an economically viable method of assessing animals such as cattle for degenerative brain diseases without it being necessary to slaughter the animal for the assessment to be made.
Various techniques are known for measuring RSA, for example those described in the documents referred to above.
For example, the paper by Genovely and Pfeifer referred to above sets out various analysis methods including the "mean circular resultant" method which relies upon the degree of clustering of R-waves relative to the respiratory cycle. This is a suitable method to be used in measuring RSA in methods in accordance with the present invention.
RSA may be measured in for example a cow by fitting an ECG monitor and a breathing monitor to the animal. Useful data representing the position in time of R-waves relative to the breathing cycle can be derived in minutes. That data can then be presented to a computer for rapid analysis to derive a measure of RSA, and that measure can be compared with a reference value or range to determine whether or not the animal should be treated as being BSE free. Thus the present invention can be applied in a cost-effective manner.
RSA may also be measured in other ways, for example by fitting only an ECG monitor to the animal, and analysing the spectral components of an ECG tachygram derived from the monitor, i.e. the beat to beat variations in heart rate. RSA appears as a high frequency peak coincident with the respiratory frequency.
It should also be noted that RSA disruption may be indicated by either an abnormally high or abnormally low level of RSA. For example, brain lesions could cut the respiratory input to the nucleus tractus solitarius (NTS), effectively eliminating RSA, or could cut the link between the NTS and the dorsal motor nucleus (DMNX), resulting in an abnormal amplification of RSA.
An embodiment of the present invention will now be described, by way of example, with reference to the accompanying drawings, in which;
  • Figure 1 is a schematic representation of the lungs/brain/heart control loop;
  • Figure 2 is an illustration in greater detail of part of Figure 1;
  • Figure 3 is a representation of data obtained from a normal mammal;
  • Figure 4 is a representation of data to be expected from a mammal the condition of which is such that the lungs/brain/heart control loop has been severely disrupted so as to suppress RSA;
  • Figures 5 and 6 represent data obtained from a cow not infected with BSE;
  • Figures 7 and 8 represent data obtained from a cow exhibiting visible symptoms of BSE;
  • Figure 9 is a table summarising data obtained from a sample of ten cows;
  • Figure 10 represents the standard deviation and mean R-R intervals set out in the table of Figure 9; and
  • Figure 11 represents the filtered FFT areas and peaks set out in the table of Figure 9.
  • Referring to Figures 1 and 2, the lungs 1 expand and contract as a result of normal respiration. Stretch receptors in the wall of the lungs generate signals which are transmitted over nerves represented by line 2 to the brain stem or medulla 3. Signals from the medulla are transmitted on nerves represented by the line 4 to the heart 5. Damage to the medulla will also of course disrupt the transmission of signals from the cerebral cortex 6 but damage to the cerebral cortex will not directly affect the lungs/brain/heart control loop.
    The medulla 3 incorporates the nucleus tractus solitarius (NTS), the nucleus ambiguus (NA) and the dorsal motor nucleus (DMNX). Signals from the lungs are delivered to the NTS which in turn supplies signals to the NA 8 and the DMNX 9. The NA and DMNX send separate signals on nerves represented by lines 10 and 11 to the heart.
    It is believed that BSE and CJD and similar degenerative brain diseases reduce the numbers of neurons in the NTS, NA and DMNX nuclei. Any reduction in the numbers of neurons in these nuclei will inevitably suppress or otherwise disrupt the operation of the lungs/brain/heart control loop. RSA is an accurate representation of the stability of that control loop.
    The present invention may be implemented using equipment identical to that described in the above mentioned International patent application which was originally intended for use in the monitoring of the depth of anaesthesia. Further information can be gained from that application, but in brief R-waves are detected, the position of those R-waves relative to the respiratory cycle is determined, and the degree of clustering of those R-waves relative to the respiratory cycles is assessed. The assessment of the degree of clustering is then compared with a reference value which represents the level of significance of the data, the level of significance being a function of the volume of data relied upon to produce the estimate of the degree of clustering.
    Figure 3 represents outputs which can be expected from a healthy mammal. The regular line 12 represents the reference level. The irregular line 13 represents the measured RSA. It will be noted that the two signals are of the same order of magnitude and that the signal 13 is sometimes greater than and sometime less than the reference level 12.
    Figure 4 represents outputs which can be expected from a mammal in which the lung/brain/heart control loop has been disrupted for example as a result of diabetes, anaesthesia or the formation of lesions in the brain stem. It will be noted that the line 12 remains much as it would be in a healthy subject. This indicates that good quality data is being assessed. In contrast, the line 13 indicates a greatly suppressed RSA level which is substantially constant over time. The two cases illustrated in Figures 3 and 4 are clearly distinguishable.
    If a herd of cows is to be selectively killed to remove those cows which it is believed may be suffering from BSE, the individual cows could be assessed to produce plots corresponding to those illustrated in Figures 3 and 4. A cow showing results similar to those of Figure 3 could be readily deemed uninfected with BSE whereas a cow showing results as shown in Figure 4 might be suffering from BSE and therefore a decision might be taken to kill that cow and to prevent its carcass entering the food chain.
    The representation data shown in Figures 3 and 4 could be produced in accordance with the method as described in the abovementioned International patent application, that is by analysing the degree of clustering of a series of R-waves relative to the respiratory cycles in which they occur, applying a test for randomness to the analysed series of R-waves to derive a reference value representing a predetermined significance level for clustering of the R-waves relative to the respiratory cycles, and comparing the reference value to the measurement value to derive a measure of the degree to which the lung/brain/heart control loop has been disrupted. An animal disposal procedure could be based on the assumption that if disruption has occurred it will be assumed that this results from the progress of a degenerative brain disease, and hence that animal will be destroyed and its carcass not admitted into the food chain.
    A pilot study has been conducted to test the feasibility of making routine recordings of heart rate variability (HRV) in cows to assess RSA and thereby assess the probability of a particular cow having BSE.
    A sample of ten cows was examined, the cows in the sample being selected from three groups, that is normal, inoculated with BSE but not exhibiting clinical signs, and animals exhibiting clinical signs of BSE. Each cow was positioned in a crush to facilitate handling. Standard electrocardiogram (ECG) electrodes were affixed to each of the cows in turn. The resultant ECG outputs were amplified using a standard amplifier and digitised using a standard laboratory interface. Three hundred seconds of ECG data was collected from each cow.
    No respiratory signal was recorded with the ECG, so the level of RSA was derived by performing power spectral analysis on the ECG R-R wave interval, in order to estimate the amount of power within the respiratory frequency domain. Peak power and total power was derived for the frequency band 0.05 to 0.4 Hz. This deliberately wide band ensured that respiratory effects on HRV would be included in the analysis, at whatever frequency the cow was breathing. Standard software was used to analyse the resultant data.
    The data represented in Figures 5 and 6 was obtained from a cow not suffering from BSE. The data shown in Figure 5 is in the form of the raw high resolution ECG output, and a tachygram showing the level of HRV (degree of variation in the upper line from the horizontal, more HRV being represented as more deviation in the line). Figure 6 shows the 512 point FFT (low pass and high pass filtered) for the same data as represented by Figure 5. Figures 7 and 8 present equivalent data derived from a cow exhibiting visible symptoms of BSE. The BSE infected cow clearly shows an abnormal level of HRV (and therefore RSA) in comparison with the normal cow.
    Data derived from each of the ten cows in the sample is presented in Figure 9. It will be seen that animals 9 and 6 show extremely disrupted levels of HRV which correlates well with the fact that these two animals were exhibiting immediately apparent symptoms of BSE. No clear pattern was apparent in the case of the inoculated animal 5 and further analysis of results from those animals would be required to enable the development of the disease over time to be correlated with changes in the monitored HRV. The results do however provide strong support for the suggestion that HRV analysis may form the basis for a reliable non-invasive simple test for BSE in the field.
    The text of this patent specification has focused on bovine spongiform encephalopathy but it will be appreciated that the invention is equally applicable to any degenerative brain disease in which lesions are formed progressively in the brain. Specifically the invention is applicable to the detection of any transmissible spongiform encephalopathy.

    Claims (9)

    1. A method for selecting mammalian animal carcasses for introduction into the human food chain, wherein before slaughter the respiratory sinus arrhythmia of the animals to be slaughtered is measured, and only those carcasses from animals for which the associated RSA is normal are selected.
    2. A method according to claim 1, wherein animals are selected if the RSA is within a predetermined range.
    3. A method for selecting mammalian animals for slaughter, wherein the respiratory sinus arrhythmia of the animals is assessed, and animals with an abnormal measured RSA are slaughtered.
    4. A method according to claim 3, wherein animals are selected if the measured RSA is outside a predetermined range.
    5. A method according to any preceding claim, wherein a measure of RSA is computed by analysing the degree of clustering of a series of R-waves relative to the respiratory cycles in which they occur, a test for randomness is applied to the analysed series of R-waves to derive a reference value representing a predetermined significance level for clustering of the R-waves relative to the respiratory cycles, and the measurement value is compared with the reference value, a substantial difference between the compared values leading to the assumption that the mammal is suffering from a degenerative brain disease.
    6. A method according to any one of claims 1 to 4, wherein a measure of RSA is computed by analysing an ECG tachygram to detect high frequency peaks coincident with the respiratory frequency.
    7. An animal carcass selection apparatus, comprising monitoring means for deriving a measure of the respiratory sinus arrhythmia of animals prior to slaughter, and means for comparing this measure with a reference value or range and hence producing an output indicating whether or not individual animals have normal RSA, the output being used to enable the selection of carcasses of only those animals for which the output indicates normal RSA.
    8. A selection apparatus for selecting animals for slaughter, comprising monitoring means for deriving a measure of the respiratory sinus arrhythmia of the animals, and means for comparing this measure with a reference value or range and hence producing an output indicating which animals have an abnormal measured RSA to enable the slaughter of such animals.
    9. An apparatus according to claim 7 or 8, comprising an ECG monitor, and a breathing monitor.
    EP97916578A 1996-04-17 1997-04-15 Analysis for the presence of degenerative brain disease Expired - Lifetime EP0897283B1 (en)

    Priority Applications (1)

    Application Number Priority Date Filing Date Title
    DK97916578T DK0897283T3 (en) 1996-04-17 1997-04-15 Analysis for the presence of degenerative brain disease

    Applications Claiming Priority (7)

    Application Number Priority Date Filing Date Title
    GB9607970 1996-04-17
    GB9607970A GB9607970D0 (en) 1996-04-17 1996-04-17 Analysis for the presence of degenerative brain diseasse
    GB9623759A GB9623759D0 (en) 1996-11-15 1996-11-15 Analysis for the presence of degenerative brain disease
    GB9623759 1996-11-15
    GB9704300 1997-03-01
    GB9704300A GB9704300D0 (en) 1997-03-01 1997-03-01 Analysis for the presence of degenerative brain disease
    PCT/GB1997/001043 WO1997038627A1 (en) 1996-04-17 1997-04-15 Analysis for the presence of degenerative brain disease

    Publications (2)

    Publication Number Publication Date
    EP0897283A1 EP0897283A1 (en) 1999-02-24
    EP0897283B1 true EP0897283B1 (en) 2004-10-13

    Family

    ID=27268245

    Family Applications (1)

    Application Number Title Priority Date Filing Date
    EP97916578A Expired - Lifetime EP0897283B1 (en) 1996-04-17 1997-04-15 Analysis for the presence of degenerative brain disease

    Country Status (11)

    Country Link
    US (1) US6217521B1 (en)
    EP (1) EP0897283B1 (en)
    JP (1) JP2001502193A (en)
    AT (1) ATE279143T1 (en)
    AU (1) AU736454B2 (en)
    CA (1) CA2251831A1 (en)
    DE (1) DE69731194T2 (en)
    DK (1) DK0897283T3 (en)
    ES (1) ES2230599T3 (en)
    PT (1) PT897283E (en)
    WO (1) WO1997038627A1 (en)

    Families Citing this family (5)

    * Cited by examiner, † Cited by third party
    Publication number Priority date Publication date Assignee Title
    GB9624280D0 (en) 1996-11-22 1997-01-08 Univ Glasgow Apparatus and method for measuring cardiac vagal tone
    US6591991B2 (en) * 2001-08-06 2003-07-15 Luce Belle Collapsible tire stand
    US20030092090A1 (en) * 2001-11-14 2003-05-15 Kiamars Hajizadeh Rapid prion-detection device, system, and test kit
    US7045297B2 (en) * 2001-11-14 2006-05-16 Prion Developmental Laboratories, Inc. Rapid prion-detection assay
    GB2399886A (en) * 2003-03-26 2004-09-29 Secr Defence Identifying degenerative brain disease using EEG or EMG measurements

    Family Cites Families (3)

    * Cited by examiner, † Cited by third party
    Publication number Priority date Publication date Assignee Title
    US4510944A (en) * 1982-12-30 1985-04-16 Porges Stephen W Method and apparatus for evaluating rhythmic oscillations in aperiodic physiological response systems
    GB9022623D0 (en) * 1990-10-18 1990-11-28 Univ Manchester Depth of anaesthesia monitoring
    GB9307523D0 (en) * 1993-04-13 1993-06-02 Mini Agriculture & Fisheries Detection of cns gases

    Also Published As

    Publication number Publication date
    ATE279143T1 (en) 2004-10-15
    AU736454B2 (en) 2001-07-26
    EP0897283A1 (en) 1999-02-24
    DE69731194D1 (en) 2004-11-18
    AU2518997A (en) 1997-11-07
    PT897283E (en) 2005-02-28
    CA2251831A1 (en) 1997-10-23
    DK0897283T3 (en) 2005-02-14
    US6217521B1 (en) 2001-04-17
    WO1997038627A1 (en) 1997-10-23
    JP2001502193A (en) 2001-02-20
    DE69731194T2 (en) 2005-10-20
    ES2230599T3 (en) 2005-05-01

    Similar Documents

    Publication Publication Date Title
    EP0371424B1 (en) Monitoring device for the diagnosis of apnea
    Flink et al. Guidelines for the use of EEG methodology in the diagnosis of epilepsy: International league against epilepsy: Commission report commission on European Affairs: Subcommission on European Guidelines
    US7433732B1 (en) Real-time brain monitoring system
    Ayoubian et al. Automatic seizure detection in SEEG using high frequency activities in wavelet domain
    Parker et al. Comparison of Polar® heart rate interval data with simultaneously recorded ECG signals in horses
    US20160317073A1 (en) Method and apparatus for assessing cardiac and/or mental health
    US10342449B2 (en) Electrocardiogram device and methods
    Chini et al. Neural correlates of anesthesia in newborn mice and humans
    BR112019011229A2 (en) seizure semiology including muscle signals collected from electroencephalography electrodes
    Konold et al. Time and frequency domain analysis of heart rate variability in cattle affected by bovine spongiform encephalopathy
    JP2019515732A (en) System and method for seizure characterization
    Fraga et al. Towards an EEG-based biomarker for Alzheimer's disease: Improving amplitude modulation analysis features
    Ter Woort et al. Validation of an equine fitness tracker: heart rate and heart rate variability
    CA2974743A1 (en) Diagnostic method and apparatus for brain injury based on emg frequency power spectra analysis
    Scott et al. The neurophysiological responses of concussive impacts: a systematic review and meta-analysis of transcranial magnetic stimulation studies
    EP0897283B1 (en) Analysis for the presence of degenerative brain disease
    Dijkstra et al. Frequency and characteristic features of REM sleep without atonia
    Yu et al. Electrophysiological biomarkers of epileptogenicity in Alzheimer’s disease
    Kołodziej et al. A new method of cardiac sympathetic index estimation using a 1D-convolutional neural network
    Gusev et al. Performance evaluation of atrial fibrillation detection
    Moens et al. Heart rate variability is not suitable as a surrogate marker for pain intensity in patients with chronic pain
    de Araujo Furtado et al. Analyzing large data sets acquired through telemetry from rats exposed to organophosphorous compounds: an EEG study
    KR20200142441A (en) Measurement apparatus of altered cortical region using functional network and method thereof
    Bibina et al. Time-frequency methods for diagnosing alzheimer's disease using eeg: A technical review
    Pomfrett et al. The vagus nerve as a conduit for neuroinvasion, a diagnostic tool, and a therapeutic pathway for transmissible spongiform encephalopathies, including variant Creutzfeld Jacob disease

    Legal Events

    Date Code Title Description
    PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

    Free format text: ORIGINAL CODE: 0009012

    17P Request for examination filed

    Effective date: 19981022

    AK Designated contracting states

    Kind code of ref document: A1

    Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

    RAP1 Party data changed (applicant data changed or rights of an application transferred)

    Owner name: THE VICTORIA UNIVERSITY OF MANCHESTER

    17Q First examination report despatched

    Effective date: 20030206

    GRAP Despatch of communication of intention to grant a patent

    Free format text: ORIGINAL CODE: EPIDOSNIGR1

    GRAS Grant fee paid

    Free format text: ORIGINAL CODE: EPIDOSNIGR3

    GRAA (expected) grant

    Free format text: ORIGINAL CODE: 0009210

    AK Designated contracting states

    Kind code of ref document: B1

    Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

    REG Reference to a national code

    Ref country code: GB

    Ref legal event code: FG4D

    REG Reference to a national code

    Ref country code: CH

    Ref legal event code: EP

    REG Reference to a national code

    Ref country code: IE

    Ref legal event code: FG4D

    REF Corresponds to:

    Ref document number: 69731194

    Country of ref document: DE

    Date of ref document: 20041118

    Kind code of ref document: P

    REG Reference to a national code

    Ref country code: SE

    Ref legal event code: TRGR

    REG Reference to a national code

    Ref country code: DK

    Ref legal event code: T3

    REG Reference to a national code

    Ref country code: CH

    Ref legal event code: NV

    Representative=s name: RITSCHER & PARTNER AG

    REG Reference to a national code

    Ref country code: GB

    Ref legal event code: 732E

    REG Reference to a national code

    Ref country code: GR

    Ref legal event code: EP

    Ref document number: 20050400116

    Country of ref document: GR

    REG Reference to a national code

    Ref country code: PT

    Ref legal event code: SC4A

    Free format text: AVAILABILITY OF NATIONAL TRANSLATION

    Effective date: 20050106

    PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

    Ref country code: GR

    Payment date: 20050311

    Year of fee payment: 9

    PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

    Ref country code: MC

    Payment date: 20050330

    Year of fee payment: 9

    PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

    Ref country code: NL

    Payment date: 20050403

    Year of fee payment: 9

    PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

    Ref country code: SE

    Payment date: 20050406

    Year of fee payment: 9

    PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

    Ref country code: DE

    Payment date: 20050407

    Year of fee payment: 9

    PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

    Ref country code: FR

    Payment date: 20050408

    Year of fee payment: 9

    PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

    Ref country code: PT

    Payment date: 20050412

    Year of fee payment: 9

    PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

    Ref country code: AT

    Payment date: 20050413

    Year of fee payment: 9

    PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

    Ref country code: FI

    Payment date: 20050414

    Year of fee payment: 9

    Ref country code: IE

    Payment date: 20050414

    Year of fee payment: 9

    PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

    Ref country code: DK

    Payment date: 20050415

    Year of fee payment: 9

    PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

    Ref country code: LU

    Payment date: 20050420

    Year of fee payment: 9

    REG Reference to a national code

    Ref country code: ES

    Ref legal event code: FG2A

    Ref document number: 2230599

    Country of ref document: ES

    Kind code of ref document: T3

    PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

    Ref country code: ES

    Payment date: 20050527

    Year of fee payment: 9

    PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

    Ref country code: BE

    Payment date: 20050615

    Year of fee payment: 9

    PLBE No opposition filed within time limit

    Free format text: ORIGINAL CODE: 0009261

    STAA Information on the status of an ep patent application or granted ep patent

    Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

    ET Fr: translation filed
    26N No opposition filed

    Effective date: 20050714

    PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

    Ref country code: GB

    Payment date: 20060412

    Year of fee payment: 10

    PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

    Ref country code: CH

    Payment date: 20060413

    Year of fee payment: 10

    PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

    Ref country code: FI

    Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

    Effective date: 20060415

    Ref country code: AT

    Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

    Effective date: 20060415

    PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

    Ref country code: SE

    Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

    Effective date: 20060416

    PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

    Ref country code: IE

    Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

    Effective date: 20060417

    Ref country code: ES

    Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

    Effective date: 20060417

    PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

    Ref country code: MC

    Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

    Effective date: 20060430

    Ref country code: LU

    Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

    Effective date: 20060430

    Ref country code: BE

    Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

    Effective date: 20060430

    PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

    Ref country code: IT

    Payment date: 20060430

    Year of fee payment: 10

    PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

    Ref country code: DK

    Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

    Effective date: 20060501

    PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

    Ref country code: PT

    Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

    Effective date: 20061016

    PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

    Ref country code: NL

    Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

    Effective date: 20061101

    Ref country code: DE

    Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

    Effective date: 20061101

    REG Reference to a national code

    Ref country code: DK

    Ref legal event code: EBP

    EUG Se: european patent has lapsed
    REG Reference to a national code

    Ref country code: PT

    Ref legal event code: MM4A

    Free format text: LAPSE DUE TO NON-PAYMENT OF FEES

    Effective date: 20061016

    NLV4 Nl: lapsed or anulled due to non-payment of the annual fee

    Effective date: 20061101

    REG Reference to a national code

    Ref country code: IE

    Ref legal event code: MM4A

    REG Reference to a national code

    Ref country code: FR

    Ref legal event code: ST

    Effective date: 20061230

    REG Reference to a national code

    Ref country code: ES

    Ref legal event code: FD2A

    Effective date: 20060417

    REG Reference to a national code

    Ref country code: CH

    Ref legal event code: PL

    GBPC Gb: european patent ceased through non-payment of renewal fee

    Effective date: 20070415

    BERE Be: lapsed

    Owner name: THE *VICTORIA UNIVERSITY OF MANCHESTER

    Effective date: 20060430

    PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

    Ref country code: LI

    Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

    Effective date: 20070430

    Ref country code: CH

    Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

    Effective date: 20070430

    PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

    Ref country code: GB

    Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

    Effective date: 20070415

    Ref country code: FR

    Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

    Effective date: 20060502

    PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

    Ref country code: GR

    Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

    Effective date: 20061102

    PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

    Ref country code: IT

    Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

    Effective date: 20070415